Sanofi/Regeneron begin Phase III ODYSSEY with first-in-class PCSK9 inhibitor
This article was originally published in Scrip
Executive Summary
It what may indeed prove to be an epic journey full of adventure and hardship, Sanofi and Regeneron have now announced the official launch of the Phase III development programme, dubbed ODYSSEY, for their novel treatment to reduce LDL-cholesterol, SAR236553/REGN727.